Scarica l'app Stockscreener
1.5308
5.21%
-0.0992
Precedente Chiudi:
$1.63
Aprire:
$1.53
Volume 24 ore:
150.24K
Relative Volume:
0.61
Capitalizzazione di mercato:
$122.25M
Reddito:
-
Utile/perdita netta:
$-30.15M
Rapporto P/E:
-1.3084
EPS:
-1.17
Flusso di cassa netto:
$-31.63M
1 W Prestazione:
-18.68%
1M Prestazione:
-25.00%
6M Prestazione:
-23.89%
1 anno Prestazione:
+90.74%
Intervallo 1D:
$1.505
$1.5849
Intervallo di 1 settimana:
$1.505
$1.89
Portata 52W:
$0.77
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Nome
Context Therapeutics Inc
Settore
Industria
Telefono
267-225-7416
Indirizzo
2001 MARKET STREET, PHILADELPHIA
Confronta CNTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| CNTX | 1.535 | 122.25M | 0 | -30.15M | -31.63M | -1.17 |
| VRTX | 450.30 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.35 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.08 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.36 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.34 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Context Therapeutics Inc Borsa (CNTX) Ultime notizie
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MyChesCo
Tango Therapeutics director Mace Rothenberg acquires $74,000 in stock - Investing.com
Avidity Partners Management LP Bolsters Stake in Context Therape - GuruFocus.com
Blue Owl Capital Holdings LP Acquires Shares in Context Therapeu - GuruFocus.com
GREAT POINT PARTNERS LLC Adjusts Stake in Context Therapeutics I - GuruFocus.com
Driehaus Capital Management LLC Acquires Shares in Apogee Therap - GuruFocus.com
Patient With Sickle Cell Disease Dies From Complications Related to Busulfan-Conditioning Following Treatment With Beam’s Base-Editing HSC Therapy BEAM-101 - CGTLive™
Research Analysts Set Expectations for CNTX FY2024 Earnings - MarketBeat
Circle S.p.A. Advances Digitalization in Logistics - MSN
Context Therapeutics (NASDAQ:CNTX) Announces Earnings Results - MarketBeat
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment - MyChesCo
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MyChesCo
Redeemer Health Operating Deficit Surpasses $50 Million in Fiscal 2024 - MSN
Context Therapeutics Announces Q3 2024 Financial Results and Strategic Advances - MyChesCo
Keiretsu Forum Honors Top Innovators at Investor Capital Expo - MyChesCo
3 Promising US Penny Stocks With At Least $90M Market Cap - Simply Wall St
Century Therapeutics Expands Clinical Focus and Reports Steady Financials for Q3 2024 - MyChesCo
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - StockTitan
Mineralys Therapeutics Set to Engage with Investors at Key Conferences - MyChesCo
Viatris Inc. (NASDAQ:VTRS) Q3 2024 Earnings Call Transcript - MSN
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Hudson Bay Capital Management LP Acquires Shares in Context Ther - GuruFocus.com
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - The Manila Times
Alto Ingredients, Inc. Reports Third Quarter 2024 Results - The Manila Times
Context Therapeutics Expands Pipeline Despite $17.5M Loss; $84.8M Cash Runway Into 2027 | CNTX Stock News - StockTitan
Join Century Therapeutics at Guggenheim’s Healthcare Innovation Conference! - MyChesCo
Stifel maintains $69 target on Beam Therapeutics stock - Investing.com
Stifel maintains $69 target on Beam Therapeutics stock By Investing.com - Investing.com UK
Protect Your Health: Discover the Life-Saving Potential of Early Lung Cancer Screenings at Local Hospitals - MyChesCo
Carisma Therapeutics Welcomes Sohanya Cheng to Board of Directors - MyChesCo
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, - openPR
West Pharmaceutical Services Announces Upcoming Conference Presentations - MyChesCo
Unpacking Q3 Earnings: Herbalife (NYSE:HLF) In The Context Of Other Consumer Staples Stocks - Yahoo Finance
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - StockTitan
Windtree Therapeutics announces $27.24 million equity sale option - Investing.com
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 17% of holdings value - Simply Wall St
Context Therapeutics to Engage Investors at November Conferences - MyChesCo
Intensity Therapeutics grants stock options to top executives - Investing.com
Context Therapeutics Inc (NASDAQ: CNTX) Gains 14.50% In Early Trade; What Lies Ahead? - Stocks Register
Context Therapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewswire
Tolerance Bio Secures $17.2 Million to Advance Immune Disease Therapies - MyChesCo
Er +/Her2 -Ve Breast Cancer Pipeline 2024: Clinical Trials - openPR
National Secure Transport Expands Cash Services to Illinois with C3 Industries - MyChesCo
Context Therapeutics to Showcase Promising Cancer Therapy at SITC Annual Meeting - MSN
Alcura Secures MIA License to Enhance Cell and Gene Therapy Importation - MSN
Context Therapeutics Announces Poster Presentation at the - GlobeNewswire
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - StockTitan
LVMH shows good resilience in the current context - Yahoo Finance
Context Therapeutics Inc Azioni (CNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):